Requires MaineCare to cover certain weight loss medications for obesity treatment.
Mandates the Department of Health and Human Services to reimburse for glucagon-like peptide-1 receptor agonists approved by the FDA for obesity treatment under the MaineCare program. It restricts reimbursement to medications prescribed by primary care providers or bariatric specialists and requires prior authorization for these medications.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.